Early and Late Toxicities of Chimeric Antigen Receptor T-Cells

As commercial utilization of CAR T-cells become more widely available and novel approaches continue to be developed, the number of patients receiving CAR T-cells will exponentially increase. Thus, optimizing management of more well established toxicities alongside recognition of rare adverse events and development of treatment strategies will remain imperative-particularly as more CAR T-cells start to become more established for use in earlier stages. For patients in whom CAR T-cells may be used to achieve a long-term durable remission, study of delayed and late toxicities will become necessary and establishing this foundation is critical to future research efforts. Finally, acknowledging that different CAR T-cell constructs and targets will be associated with unique and potentially delayed toxicities, further study to identify the biologic underpinnings of novel toxicities will be needed.